In December 2022, the Financial Conduct Authority (“FCA”) carried out a consultation on the introduction of a new regulatory gateway for firms who approve financial promotions. On 12 September 2023, the FCA published Policy...more
On 15 June 2023, The Insider Dealing (Securities and Regulated Markets) Order 2023 (the “2023 Order”) came into force. The 2023 Order seeks to align certain outdated aspects of the UK’s criminal insider dealing regime under...more
The UK Financial Conduct Authority (the “FCA”) on May 3, 2023, published consultation paper CP23/10 (the “Consultation Paper”), which sets out the FCA’s proposals to significantly reform the UK’s equity listing regime. The...more
On 24 March 2022, the Takeover Panel (the “Panel”) issued a note to advisers on disclosure of information under Rule 9 of the Takeover Code (the “Code”) and a note to advisers in relation to Rule 2.8 statements. Such notes do...more
Dechert partnered with Practical Law on their Q&A guide to mergers and acquisitions (M&A) in the life sciences sector, with a focus on pharma and medicines. The second part of the Q&A provides a high-level overview of the...more
1/28/2022
/ Acquisition Agreements ,
Clinical Trials ,
Corporate Sales Transactions ,
Healthcare ,
Life Sciences ,
Medicines and Healthcare Products Regulatory Agency (MHRA) ,
Merger Agreements ,
New Guidance ,
Pharmaceutical Industry ,
R&D ,
Regulatory Reform ,
Supply Chain ,
UK
On 17 November 2021, the Takeover Panel (the “Panel”) published Panel Bulletin 3 (the “Bulletin”) relating to the requirements of Rule 2.10(c) of the Takeover Code (the “Code”). Under Rule 2.10(c), a person who has given an...more
Regulatory Updates: Health and Care Bill: medicine information systems The Health and Care Bill was introduced to the House of Commons on 6 July 2021. Clause 85 of the Bill amends the Medicines and Medical Devices Act 2021...more
Dechert’s Healthcare Deals Conference 2021 was recently held in-person at BMA House in London and streamed live across the globe via a virtual platform.
The one-day hybrid conference brought together senior pharma,...more
On 30 April 2021, the FCA consulted on proposals to change the UK Listing Rules to remove the presumption that the listing of a Special Purpose Acquisition Company (“SPAC”) be suspended when it identifies a potential...more
On 19 August 2021, the Regulatory Horizons Council (the “RHC”) published a report setting out recommendations for reforming the regulation of medical devices in the UK (the “Report”). The RHC is an independent expert...more
The value of the global medicinal cannabis market is projected to reach US$62.7 billion by 2024, with over US$22 billion of that market generated by Europe and an estimated excess of £2 billion likely to be generated in the...more
6/29/2021
/ Cannabis-Related Businesses (CRBs) ,
Financial Conduct Authority (FCA) ,
Investment ,
Investment Funds ,
Investors ,
London Stock Exchange ,
Marijuana ,
Marijuana Related Businesses ,
Medical Marijuana ,
Popular ,
UK
The European Commission has issued new Standard Contractual Clauses designed to facilitate international transfers of personal data in compliance with the GDPR. The new provisions better reflect the variety of global data...more
On 29 April 2021 the Financial Services Bill 2019-21 received Royal Assent and the Financial Services Act 2021 (the “Act”) was published. This OnPoint sets out three key aspects of the Act and the implications for issuers....more
Share options or other equity incentives (such as growth shares) are an effective way to align the interests of investors with those individuals managing the company on a day-to-day basis. As a result, they are a common...more
The European Commission’s antitrust arm, DG COMP, has for the second time publicly confirmed that a COVID-19 initiative among pharmaceutical companies is compliant with EU antitrust laws. It did so by way of a “comfort...more
One of the most effective ways to incentivise staff, in particular senior employees, is to offer them the opportunity to purchase stock or shares in a group company. U.S. companies often operate stock and other incentive...more
Following the successful run of the government-backed Future Fund, the British Business Bank has announced that it is set to launch a further fund for development, Future Fund: Breakthrough. This scheme is set to provide up...more
Other recent notable industry transactions: Thermo Fisher Scientific Inc. completed the acquisition of Henogen SA, Novasep's viral vector manufacturing business in Belgium for approximately €725 million in cash....more
The National Institute for Health and Care Excellence public consultation -
The National Institute for Health and Care Excellence (“NICE”) has commenced a public consultation on its technology evaluation process when...more
Recent notable industry transactions. Royal Philips announced that it has agreed to acquire Capsule Technologies, Inc., a provider of medical device integration and data technologies for hospitals and healthcare...more
MHRA updates post-transition guidance Since 31 December 2020, the Medicines and Healthcare products Regulatory Agency (MHRA) has been updating various aspects of the regulatory regime for medicines and medical devices...more
Recent notable industry transactions.
The Alan Turing Institute, the Royal Statistical Society and the UK Department of Health and Social Care's Joint Biosecurity Centre finalised a partnership agreement in relation to the...more
12/2/2020
/ AstraZeneca ,
Bayer ,
Coronavirus/COVID-19 ,
Corporate Sales Transactions ,
Infectious Diseases ,
Life Sciences ,
Merck ,
Mylan Pharmaceuticals ,
Pfizer ,
Pharmaceutical Industry ,
UK
Medicines and Medical Devices Bill (MMDB) – The MMDB is intended to act as the primary UK legislation specifying powers that would enable the regulatory regimes for human medicines, clinical trials, veterinary medicines and...more
As the most tax advantageous HMRC approved share option scheme available, the Enterprise Management Incentive (EMI) scheme has long been the preferred form of incentive for eligible early and mid-stage UK-based life science...more
The UK has announced a bill proposing a new system to screen transactions for national security risk, separate from the system of merger review operated by the Competition and Markets Authority. The National Security and...more
12/2/2020
/ Antitrust Provisions ,
Biotechnology ,
Foreign Investment ,
Legislative Agendas ,
Life Sciences ,
National Security ,
Pharmaceutical Industry ,
R&D ,
Regulatory Agenda ,
UK ,
UK Parliament